Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21

Ultrasound in Obstetrics and Gynecology

Volumn 33, Issue 6, 2009, Pages 657-664

  Kagan, K O ^a,c   Wright, D ^b   Etchegaray, A ^a   Zhou, Y ^a   Nicolaides, K H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

First trimester; Nuchal translucency; Quality assurance; Screening; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; FALSE POSITIVE RESULT; GESTATIONAL AGE; MATERNAL AGE; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PRIORITY JOURNAL; SIMULATION; TRISOMY 21;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; SENSITIVITY AND SPECIFICITY;

EID: 66449110563     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.6370     Document Type: Article

References (12)

1. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomy 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free β-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008; 19: 1968-1975.
2. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-346. (Pubitemid 28352196)
3. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-V383.
4. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
5. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
6. Office for National Statistics. Birth Statistics. Review of the Registrar General on Births and Patterns of Family Building in England and Wales. 2000-2002. Series FM1, numbers 29-31. Stationery Office: London, 7.
7. Cuckle HS,Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387-402. (Pubitemid 17068086)
8. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167-170. (Pubitemid 29176889)
9. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of first trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol (in press).
10. Logghe H, Cuckle H, Sehmi I. Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. Prenat Diagn 2003; 23: 389-392. (Pubitemid 36596968)
11. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM; SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-77.
12. Snijders RJ, Thom EA, Zachary JM, Platt LD, Greene N, Jackson LG, Sabbagha RE, Filkins K, Silver RK, Hogge WA, Ginsberg NA, Beverly S, Morgan P, Blum K, Chilis P, Hill LM, Hecker J, Wapner RJ. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19: 353-359. (Pubitemid 34592131)